Total submissions: 37
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Evidence- |
RCV000113692 | SCV000245106 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2015-01-12 | reviewed by expert panel | curation | Class 1 not pathogenic based on frequency >1% in an outbred sampleset. Frequency 0.02642 (African), derived from 1000 genomes (2012-04-30). |
Labcorp Genetics |
RCV000167851 | SCV000073134 | benign | Hereditary breast ovarian cancer syndrome | 2024-02-01 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000113692 | SCV000154081 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2014-03-18 | criteria provided, single submitter | literature only | |
Ambry Genetics | RCV000128918 | SCV000172785 | benign | Hereditary cancer-predisposing syndrome | 2014-11-19 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Eurofins Ntd Llc |
RCV000120355 | SCV000202294 | benign | not specified | 2013-12-06 | criteria provided, single submitter | clinical testing | |
Pathway Genomics | RCV000113692 | SCV000223770 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2014-10-30 | criteria provided, single submitter | clinical testing | |
Genomic Diagnostic Laboratory, |
RCV000167851 | SCV000257617 | likely benign | Hereditary breast ovarian cancer syndrome | 2015-04-14 | criteria provided, single submitter | clinical testing | |
Michigan Medical Genetics Laboratories, |
RCV000113692 | SCV000267805 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2016-04-21 | criteria provided, single submitter | clinical testing | |
CHEO Genetics Diagnostic Laboratory, |
RCV000768605 | SCV000324839 | benign | Breast and/or ovarian cancer | 2016-01-26 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000383466 | SCV000383754 | likely benign | Fanconi anemia complementation group D1 | 2018-01-19 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases allowed determination this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. |
Illumina Laboratory Services, |
RCV000113692 | SCV000383755 | likely benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2018-01-19 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. The evidence from the literature, in combination with allele frequency data from public databases where available, was sufficient to determine this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000167851 | SCV000494340 | benign | Hereditary breast ovarian cancer syndrome | 2014-04-15 | criteria provided, single submitter | clinical testing | |
Laboratory for Molecular Medicine, |
RCV000120355 | SCV000538462 | benign | not specified | 2016-03-28 | criteria provided, single submitter | clinical testing | Variant identified in a genome or exome case(s) and assessed due to predicted null impact of the variant or pathogenic assertions in the literature or databases. Disclaimer: This variant has not undergone full assessment. The following are preliminary notes: ExAC: 2.7% (262/9870) African chromosomes |
Baylor Genetics | RCV000465613 | SCV000541038 | benign | Familial cancer of breast | 2017-02-23 | criteria provided, single submitter | clinical testing | |
Cancer Genetics and Genomics Laboratory, |
RCV000120355 | SCV000586971 | benign | not specified | 2017-04-18 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV000514662 | SCV000602876 | benign | not provided | 2023-11-24 | criteria provided, single submitter | clinical testing | |
Center for Pediatric Genomic Medicine, |
RCV000514662 | SCV000610790 | benign | not provided | 2017-05-30 | criteria provided, single submitter | clinical testing | |
Color Diagnostics, |
RCV000128918 | SCV000683843 | benign | Hereditary cancer-predisposing syndrome | 2015-03-05 | criteria provided, single submitter | clinical testing | |
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000113692 | SCV000744507 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2015-09-21 | criteria provided, single submitter | clinical testing | |
Institute for Biomarker Research, |
RCV000128918 | SCV000747801 | likely benign | Hereditary cancer-predisposing syndrome | 2018-01-16 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV000120355 | SCV000805755 | benign | not specified | 2017-04-13 | criteria provided, single submitter | clinical testing | |
National Health Laboratory Service, |
RCV000167851 | SCV002025809 | benign | Hereditary breast ovarian cancer syndrome | 2022-04-19 | criteria provided, single submitter | clinical testing | |
Genetics Program, |
RCV000167851 | SCV002515138 | benign | Hereditary breast ovarian cancer syndrome | 2021-11-01 | criteria provided, single submitter | research | |
Sema4, |
RCV000128918 | SCV002536294 | benign | Hereditary cancer-predisposing syndrome | 2020-06-25 | criteria provided, single submitter | curation | |
Fulgent Genetics, |
RCV002504934 | SCV002809295 | benign | Familial cancer of breast; Breast-ovarian cancer, familial, susceptibility to, 2; Fanconi anemia complementation group D1; Medulloblastoma; Wilms tumor 1; Malignant tumor of prostate; Pancreatic cancer, susceptibility to, 2; Glioma susceptibility 3 | 2022-04-13 | criteria provided, single submitter | clinical testing | |
KCCC/NGS Laboratory, |
RCV000113692 | SCV004016842 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2023-07-07 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000514662 | SCV004132992 | benign | not provided | 2023-01-01 | criteria provided, single submitter | clinical testing | BRCA2: BP4, BS1, BS2 |
Center for Genomic Medicine, |
RCV000120355 | SCV004243056 | benign | not specified | 2024-02-06 | criteria provided, single submitter | clinical testing | |
All of Us Research Program, |
RCV000113692 | SCV004844348 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2024-02-05 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV000514662 | SCV005236523 | benign | not provided | criteria provided, single submitter | not provided | ||
ITMI | RCV000120355 | SCV000084507 | not provided | not specified | 2013-09-19 | no assertion provided | reference population | |
Breast Cancer Information Core |
RCV000113692 | SCV000147001 | uncertain significance | Breast-ovarian cancer, familial, susceptibility to, 2 | 2002-05-29 | no assertion criteria provided | clinical testing | |
Department of Pathology and Laboratory Medicine, |
RCV001353904 | SCV000592091 | benign | Malignant tumor of breast | no assertion criteria provided | clinical testing | The p.Lys2339Asn variant has been previously reported in the literature in 10/8236 proband chromosomes, and in none of the 132 control chromosomes tested (Capanu_2011_21520273, Gao_2000_11030417, Kote-Jarai_2011_21952622, Nanda_2005_16234499). It is listed in the dbSNP database as coming from a "clinical source" (ID#: rs45574331) with a MAF score of 0.006 (1000 Genomes). The variant was identified at high frequency >2.6% in African population from ExAC increasing likelihood this is a common benign polymorphism. The variant was also identified in the UMD (x19), BIC, Exome Server and the BOCs databases. In addition, in the UMD database, the p.Lys2339Asn variant was found to co-occur with a pathogenic mutation in BRCA1, c.2709_2710delTG (p.Cys903X), increasing the likelihood that the variant is a benign alteration. This residue is not conserved in mammals and computational analyses (SIFT, AlignGVGD) do not suggest a high likelihood of impact to the protein. However, this information is not predictive enough to rule out pathogenicity. In summary, based on the above information, we cannot determine the clinical significance of this variant with certainty at this time, although we would lean towards a more benign role for this variant. In summary, this variant is classified as Benign. | |
Mayo Clinic Laboratories, |
RCV000514662 | SCV000778701 | benign | not provided | 2017-12-23 | no assertion criteria provided | clinical testing | |
Clinical Genetics Laboratory, |
RCV000120355 | SCV001906102 | benign | not specified | no assertion criteria provided | clinical testing | ||
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV000120355 | SCV001956315 | benign | not specified | no assertion criteria provided | clinical testing | ||
Genome Diagnostics Laboratory, |
RCV000120355 | SCV001977807 | benign | not specified | no assertion criteria provided | clinical testing |